Discover
LYEL
Lyell Immunopharma, Inc.
11.01
2 x 7.86
2 x 13.44
bid
ask
+
0.21
1.94%
2 @ 07:30 PM
11.01 +0.00 (0.00%)
| Ytd | -64.23% | |
| 1y | -12.90% |
10.53
day range
11.04
10.46
52 week range
45.00
| Open | 10.75 | Prev Close | 10.80 | Low | 10.53 | High | 11.04 | Mkt Cap | 269.80M |
| Vol | 401.13K | Avg Vol | 180.77K | EPS | -12.69 | P/E | N/A | Forward P/E | -0.73 |
| Beta | -0.48 | Short Ratio | 6.15 | Inst. Own | 58.79% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-06 | 50-d Avg | 13.64 | 200-d Avg | 19.89 | 1yr Est | 1.00 |
| Income Statement | |||
| Total Revenue | 4.00K | ||
| Revenues (USD) | 4.00K | ||
| Gross Profit | 4.00K | ||
| Operating Expenses | 47.34M | ||
| Research and Development Expense | 39.52M | ||
| Selling, General and Administrative Expense | 9.58M | ||
| Operating Income | -47.34M | ||
| Net Income | -44.75M | ||
| Net Income Common Stock | -44.75M | ||
| Net Income Common Stock (USD) | -44.75M | ||
| Consolidated Income | -44.75M | ||
| Earnings per Basic Share | -1.92 | ||
| Earnings per Basic Share (USD) | -1.92 | ||
| Earnings per Diluted Share | -1.92 | ||
| Earning Before Interest & Taxes (EBIT) | -44.75M | ||
| Earning Before Interest & Taxes (USD) | -44.75M | ||
| Weighted Average Shares | 23.36M | ||
| Weighted Average Shares Diluted | 23.36M | ||
| Balance Sheet | |||
| Cash and Equivalents | 74.57M | ||
| Cash and Equivalents (USD) | 74.57M | ||
| Investments | 174.01M | ||
| Investments Current | 131.12M | ||
| Investments Non-Current | 42.90M | ||
| Current Assets | 213.54M | ||
| Property, Plant & Equipment Net | 47.29M | ||
| Total Assets | 311.15M | ||
| Total Debt | 36.93M | ||
| Current Liabilities | 39.87M | ||
| Debt Non-Current | 36.93M | ||
| Total Liabilities | 77.34M | ||
| Accumulated Retained Earnings (Deficit) | -1.69B | ||
| Accumulated Other Comprehensive Income | -158.00K | ||
| Shareholders Equity | 233.82M | ||
| Shareholders Equity (USD) | 233.82M | ||
| Assets Non-Current | 97.61M | ||
| Total Debt (USD) | 36.93M | ||
| Liabilities Non-Current | 37.47M | ||
| Trade and Non-Trade Payables | 3.88M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 2.22M | ||
| Net Cash Flow from Financing | 522.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -17.78M | ||
| Capital Expenditure | -251.00K | ||
| Issuance (Purchase) of Equity Shares | 522.00K | ||
| Net Cash Flow from Investing | 15.62M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 15.87M | ||
| Net Cash Flow from Operations | -33.92M | ||
| Share Based Compensation | 4.53M | ||